➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKesson
Medtronic
Baxter
AstraZeneca
Merck

Last Updated: June 12, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR TRIFAROTENE

« Back to Dashboard

All Clinical Trials for TRIFAROTENE

Trial ID Title Status Sponsor Phase Start Date Summary
NCT03738800 A Safety, Efficacy and Systemic Exposure Study of CD5789 Cream in Adults and Adolescents With Lamellar Ichthyosis Not yet recruiting Mayne Pharma International Pty Ltd Phase 2 2019-01-21 This is a phase 2 randomized, multi-center, double-blind, vehicle controlled, 12-week, safety, efficacy, and systemic exposure study followed by a 12-week open-label extension of trifarotene cream in adults and adolescents with autosomal recessive ichthyosis with lamellar scale
NCT03915860 Subject Reported Outcomes With Use of Trifarotene 50 μg/g Cream in the Treatment of Moderate Facial and Truncal Acne Vulgaris Recruiting Galderma R&D Phase 3 2019-04-08 Subject Reported Outcomes with use of Trifarotene 50 μg/g Cream in Subjects with Moderate Facial and Truncal Acne Vulgaris
NCT04451330 A Study to Compare Efficacy and Safety of Trifarotene Cream When Used With an Oral Antibiotic for the Treatment of Severe Acne Vulgaris (AV) Not yet recruiting Galderma R&D Phase 4 2020-07-01 The purpose of this study is to demonstrate that daily use of topical trifarotene (CD5789) 50 microgram per gram (mcg/g) cream when used in association with oral antibiotic is safe and effective for the treatment of severe AV.
NCT04856904 Study of Trifarotene Cream to Assess Risk of a Trophic Acne Scar Formation Not yet recruiting Galderma R&D Phase 4 2021-05-21 The purpose of this study is to evaluate the safety and efficacy of trifarotene 50 microgram per gram (mcg/g) cream compared to its vehicle on the risk of formation of atrophic acne scars after 24 weeks of treatment in facial acne participants assessed by atrophic acne scars count.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for TRIFAROTENE

Condition Name

Condition Name for TRIFAROTENE
Intervention Trials
Acne Vulgaris 3
Lamellar Ichthyosis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for TRIFAROTENE
Intervention Trials
Acne Vulgaris 3
Ichthyosis, Lamellar 1
Ichthyosis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for TRIFAROTENE

Trials by Country

Trials by Country for TRIFAROTENE
Location Trials
United States 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for TRIFAROTENE
Location Trials
Texas 1
Pennsylvania 1
New Hampshire 1
Massachusetts 1
California 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for TRIFAROTENE

Clinical Trial Phase

Clinical Trial Phase for TRIFAROTENE
Clinical Trial Phase Trials
Phase 4 2
Phase 3 1
Phase 2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for TRIFAROTENE
Clinical Trial Phase Trials
Not yet recruiting 3
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for TRIFAROTENE

Sponsor Name

Sponsor Name for TRIFAROTENE
Sponsor Trials
Galderma R&D 3
Mayne Pharma International Pty Ltd 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for TRIFAROTENE
Sponsor Trials
Industry 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Boehringer Ingelheim
Dow
Colorcon
Express Scripts
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.